menu
    • menu
    [{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Expanded Collaboration","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Biologics Inc \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Biologics Inc \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Biologics Inc \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Biologics Inc \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"AZD7442","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lonza Biologics Inc \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Biologics Inc \/ AstraZeneca"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"TAK-919","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lonza Biologics Inc \/ Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Biologics Inc \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Lenzilumab","moa":"G-CSF receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Biologics Inc \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Lonza Biologics Inc \/ Humanigen"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Kodiak Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2020","type":"Agreement","leadProduct":"Tarcocimab Tedromer","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Lonza Biologics Inc \/ Kodiak Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Lonza Biologics Inc \/ Kodiak Sciences"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Immunitas Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"IMT-009","moa":"CD161","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Biologics Inc \/ Immunitas Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Biologics Inc \/ Immunitas Therapeutics"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"aTyr Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"ATYR2810","moa":"NRP2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Biologics Inc \/ aTyr Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Biologics Inc \/ aTyr Pharma"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Lamkap Bio Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"NILK-2301","moa":"CD3\/CEACAM5","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Biologics Inc \/ Lamkap Bio Group","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Biologics Inc \/ Lamkap Bio Group"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Pionyr Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"PY265","moa":"MARCO receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Biologics Inc \/ Pionyr Immunotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Biologics Inc \/ Pionyr Immunotherapeutics"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Vaxcyte","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Expanded Collaboration","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lonza Biologics Inc \/ Vaxcyte","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Biologics Inc \/ Vaxcyte"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Anthos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Hematology","graph2":"Undisclosed","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Biologics Inc \/ Anthos Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Lonza Biologics Inc \/ Anthos Therapeutics"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Asher Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"AB359","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Biologics Inc \/ Asher Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Biologics Inc \/ Asher Biotherapeutics"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"HaemaLogiX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Dexamethasone","moa":"||KMA","graph1":"Oncology","graph2":"Phase II","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Biologics Inc \/ HaemaLogiX","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Biologics Inc \/ HaemaLogiX"}]

    Find Clinical Drug Pipeline Developments & Deals by Lonza Biologics Inc

    Menu

    Lonza Biologics Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sabirnetug

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Acumen Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Acumen Pharma Extends Lonza Collaboration for Drug Manufacturing of Sabirnetug

                            Details : Acumen collaborates with Lonza to advance the clinical development and potential future commercial launch of ACU193 (sabirnetug), which is being evaluated for Alzheimer’s disease.

                            Product Name : ACU193

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            September 26, 2024

                            Lead Product(s) : Sabirnetug

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Acumen Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sabirnetug

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Acumen Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Acumen Pharmaceuticals Collaborates with Lonza for Sabirnetug in Alzheimer's Disease

                            Details : Lonza will manufacture ACU193, a monoclonal antibody targeting toxic amyloid beta oligomers, for Alzheimer’s disease treatment.

                            Product Name : ACU193

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            April 04, 2024

                            Lead Product(s) : Sabirnetug

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Acumen Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 24-Valent Pneumococcal Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Vaxcyte

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conj...

                            Details : Under the expanded collaboration, Vaxcyte will utilise existing Lonza infrastructure to advance clinical development and commercialization of Vaxcyte’s PCV candidates, VAX-24, a 24-valent pneumococcal conjugate vaccine and VAX-31, in both the adult and...

                            Product Name : VAX-24

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 16, 2023

                            Lead Product(s) : 24-Valent Pneumococcal Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Vaxcyte

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB359

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Asher Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lonza and Asher Biotherapeutics to Collaborate on Manufacturing AB359

                            Details : Under the manufacturing agreement, Lonza will provide drug substance manufacturing for AB359 for preclinical and clinical testing.

                            Product Name : AB359

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            April 07, 2022

                            Lead Product(s) : AB359

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Asher Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KappaMab,Dexamethasone,Lenalidomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : HaemaLogiX

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            HaemaLogiX and Lonza Collaborate to Manufacture KappaMab

                            Details : Through the collaboration, Lonza will manufacture drug substance for clinical supply of HaemaLogiX’s lead drug candidate, MDX-1097 (KappaMab) for the treatment of multiple myeloma.

                            Product Name : MDX-1097

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            January 27, 2022

                            Lead Product(s) : KappaMab,Dexamethasone,Lenalidomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : HaemaLogiX

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMT-009

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Immunitas Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Lonza and Immunitas Therapeutics Announce Manufacturing Agreement to Rapidly Advance Lead Program to the Clini...

                            Details : Lonza will provide a customized version of the Ibex® Design program to rapidly advance Immunitas' lead program, IMT-009, from development candidate to IND.

                            Product Name : IMT-009

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            April 15, 2021

                            Lead Product(s) : IMT-009

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Immunitas Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATYR2810

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : aTyr Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810

                            Details : Under the terms of the agreement, Lonza will utilize its Ibex® Design, a fully integrated end-to-end program, to manufacture cGMP material for ATYR2810.

                            Product Name : ATYR2810

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            April 14, 2021

                            Lead Product(s) : ATYR2810

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : aTyr Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PY265

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Pionyr Immunotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Pionyr Immunotherapeutics Collaborates with Lonza to Support their Oncology Product Development

                            Details : Lonza to provide cell line development, process development, drug substance and drug product manufacturing for Pionyr’s monoclonal antibody candidate intended for oncology indications.

                            Product Name : PY265

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            March 29, 2021

                            Lead Product(s) : PY265

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Pionyr Immunotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZD7442

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Lonza to Manufacture AstraZeneca's COVID-19 Long-Acting Antibody Combination

                            Details : Lonza will manufacture drug substance (DS) for AZD7442 at Lonza's facilities in Portsmouth (US). Operations are expected to start in H1 2021. AstraZeneca will be one of the first companies to access Lonza's new mid-scale facilities in Portsmouth, NH (USA...

                            Product Name : AZD7442

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            October 30, 2020

                            Lead Product(s) : AZD7442

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed

                            Lonza Biologics Inc

                            U.S.A arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NILK-2301

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Lamkap Bio Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            LamKap Bio Group and Lonza Collaborate to Manufacture Bispecific Antibodies for Cancer Treatment

                            Details : Lonza will provide cell line and process development, drug substance manufacturing and drug product services of LamKap's two fully human bispecific antibody products, NILK-2301 and NILK-2401.

                            Product Name : NILK-2301

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            September 17, 2020

                            Lead Product(s) : NILK-2301

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Lamkap Bio Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth